Lysophosphatidic acids are new substrates for the phosphatase domain of soluble epoxide hydrolase

Journal of Lipid Research

Volumn 53, Issue 3, 2012, Pages 505-512

  Oguro, Ami ^a   Imaoka, Susumu ^a  

^a KWANSEI GAKUIN UNIVERSITY   (Japan)

Author keywords

Dephosphorylation; Epoxyeicosatrienoic acid; Fatty acid

Indexed keywords

4 METHYLUMBELLIFERYL PHOSPHATE; ARACHIDONOYLLYSOPHOSPHATIDIC ACID; EPOXIDE HYDROLASE; HYMECROMONE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; OLEOYLLYSOPHOSPHATIDIC ACID; PALMITOYL LYSOPHOSPHATIDIC ACID; PHOSPHATASE; PHOSPHATIDYLCHOLINE; STEAROYLLYSOPHOSPHATIDIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; LIPID ANALYSIS; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN;

CHROMATOGRAPHY, LIQUID; EPOXIDE HYDROLASES; HUMANS; LYSOPHOSPHOLIPIDS; MASS SPECTROMETRY; SUBSTRATE SPECIFICITY;

EID: 84857742347     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M022319     Document Type: Article

References (36)

1. Chacos, N., J. Capdevila, J. R. Falck, S. Manna, C. Martin-Wixtrom, S. S. Gill, B. D. Hammock, and R. W. Estabrook. 1983. The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch. Biochem. Biophys. 223: 639-648. (Pubitemid 13103208)
2. Imig, J. D. 2005. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289: F496-F503. (Pubitemid 41208461)
3. Fleming, I. 2007. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat. 82: 60-67. (Pubitemid 44880162)
4. Spector, A. A., and A. W. Norris. 2007. Action of epoxyeicosatrienoic acids on cellular function. Am. J. Physiol. Cell Physiol. 292: C996-C1012. (Pubitemid 46442641)
5. Imig, J. D., and B. D. Hammock. 2009. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8: 794-805.
6. Cronin, A., S. Mowbray, H. Durk, S. Homburg, I. Fleming, B. Fisslthaler, F. Oesch, and M. Arand. 2003. The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. Proc. Natl. Acad. Sci. USA. 100: 1552-1557. (Pubitemid 36254485)
7. Newman, J. W., C. Morisseau, T. R. Harris, and B. D. Hammock. 2003. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc. Natl. Acad. Sci. USA. 100: 1558-1563. (Pubitemid 36254486)
8. Allen, K. N., and D. Dunaway-Mariano. 2004. Phosphoryl group transfer: evolution of a catalytic scaffold. Trends Biochem. Sci. 29: 495-503. (Pubitemid 39158873)
9. Cronin, A., S. Homburg, H. Durk, I. Richter, M. Adamska, F. Frere, and M. Arand. 2008. Insights into the catalytic mechanism of human sEH phosphatase by site-directed mutagenesis and LC-MS/MS analysis. J. Mol. Biol. 383: 627-640.
10. Gomez, G. A., C. Morisseau, B. D. Hammock, and D. W. Christianson. 2004. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry. 43: 4716-4723. (Pubitemid 38509092)
11. Tran, K. L., P. A. Aronov, H. Tanaka, J. W. Newman, B. D. Hammock, and C. Morisseau. 2005. Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase. Biochemistry. 44: 12179-12187. (Pubitemid 41285716)
12. Enayetallah, A. E., and D. F. Grant. 2006. Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis. Biochem. Biophys. Res. Commun. 341: 254-260. (Pubitemid 43117412)
13. EnayetAllah, A. E., A. Luria, B. Luo, H. J. Tsai, P. Sura, B. D. Hammock, and D. F. Grant. 2008. Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase. J. Biol. Chem. 283: 36592-36598.
14. Oguro, A., K. Sakamoto, S. Suzuki, and S. Imaoka. 2009. Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth. Biol. Pharm. Bull. 32: 1962-1967.
15. Goetzl, E. J., and S. An. 1998. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J. 12: 1589-1598. (Pubitemid 28553654)
16. Anliker, B., and J. Chun. 2004. Lysophospholipid G protein-coupled receptors. J. Biol. Chem. 279: 20555-20558. (Pubitemid 38656446)
17. Samadi, N., R. Bekele, D. Capatos, G. Venkatraman, M. Sariahmetoglu, and D. N. Brindley. 2011. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie. 93: 61-70.
18. McIntyre, T. M., A. V. Pontsler, A. R. Silva, A. St Hilaire, Y. Xu, J. C. Hinshaw, G. A. Zimmerman, K. Hama, J. Aoki, H. Arai, et al. 2003. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. USA. 100: 131-136. (Pubitemid 36078041)
19. Gobeil, F., Jr., S. G. Bernier, A. Vazquez-Tello, S. Brault, M. H. Beauchamp, C. Quiniou, A. M. Marrache, D. Checchin, F. Sennlaub, X. Hou, et al. 2003. Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J. Biol. Chem. 278: 38875-38883. (Pubitemid 37221787)
20. Lee, S. H., S. Raboune, J. M. Walker, and H. B. Bradshaw. 2010. Distribution of endogenous farnesyl pyrophosphate and four species of lysophosphatidic acid in rodent brain. Int. J. Mol. Sci. 11: 3965-3976.
21. Han, G. S., and G. M. Carman. 2004. Assaying lipid phosphate phosphatase activities. Methods Mol. Biol. 284: 209-216.
22. Alderton, F., P. Darroch, B. Sambi, A. McKie, I. S. Ahmed, N. Pyne, and S. Pyne. 2001. G-protein-coupled receptor stimulation of the p42/p44 mitogen-activated protein kinase pathway is attenuated by lipid phosphate phosphatases 1, 1a, and 2 in human embryonic kidney 293 cells. J. Biol. Chem. 276: 13452-13460.
23. Sigal, Y. J., M. I. McDermott, and A. J. Morris. 2005. Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. Biochem. J. 387: 281-293. (Pubitemid 40575751)
24. Brindley, D. N., and C. Pilquil. 2009. Lipid phosphate phosphatases and signaling. J. Lipid Res. 50 (Suppl) : S225-S230.
25. Donkor, J., M. Sariahmetoglu, J. Dewald, D. N. Brindley, and K. Reue. 2007. Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J. Biol. Chem. 282: 3450-3457. (Pubitemid 47084457)
26. Reue, K., and D. N. Brindley. 2008. Thematic review series: glycerolipids. Multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolism. J. Lipid Res. 49: 2493-2503.
27. Reddy, V. S., A. K. Singh, and R. Rajasekharan. 2008. The Saccharomyces cerevisiae PHM8 gene encodes a soluble magnesium- dependent lysophosphatidic acid phosphatase. J. Biol. Chem. 283: 8846-8854.
28. Tsuda, S., S. Okudaira, K. Moriya-Ito, C. Shimamoto, M. Tanaka, J. Aoki, H. Arai, K. Murakami-Murofushi, and T. Kobayashi. 2006. Cyclic phosphatidic acid is produced by autotaxin in blood. J. Biol. Chem. 281: 26081-26088. (Pubitemid 44401814)
29. Stapleton, C. M., D. G. Mashek, S. Wang, C. A. Nagle, G. W. Cline, P. Thuillier, L. M. Leesnitzer, L. O. Li, J. B. Stimmel, G. I. Shulman, et al. 2011. Lysophosphatidic acid activates peroxisome proliferator activated receptor-gamma in CHO cells that over-express glycerol 3-phosphate acyltransferase-1. PLoS ONE. 6: e18932.
30. Enayetallah, A. E., R. A. French, and D. F. Grant. 2006. Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J. Mol. Histol. 37: 133-141.
31. Baker, D. L., P. Morrison, B. Miller, C. A. Riely, B. Tolley, A. M. Westermann, J. M. Bonfrer, E. Bais, W. H. Moolenaar, and G. Tigyi. 2002. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA. 287: 3081-3082. (Pubitemid 34633980)
32. Fang, X., D. Gaudette, T. Furui, M. Mao, V. Estrella, A. Eder, T. Pustilnik, T. Sasagawa, R. Lapushin, S. Yu, et al. 2000. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann. N. Y. Acad. Sci. 905: 188-208. (Pubitemid 30255418)
33. Xu, Y., X. J. Fang, G. Casey, and G. B. Mills. 1995. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309: 933-940.
34. Lee, J., S. Y. Park, E. K. Lee, C. G. Park, H. C. Chung, S. Y. Rha, Y. K. Kim, G. U. Bae, B. K. Kim, J. W. Han, et al. 2006. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin. Cancer Res. 12: 6351-6358. (Pubitemid 44799704)
35. Song, Y., J. Wu, R. A. Oyesanya, Z. Lee, A. Mukherjee, and X. Fang. 2009. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin. Cancer Res. 15: 492-501.
36. Elabbadi, N., C. P. Day, A. Gamouh, A. Zyad, and S. J. Yeaman. 2005. Relationship between the inhibition of phosphatidic acid phosphohydrolase-1 by oleate and oleoyl-CoA ester and its apparent translocation. Biochimie. 87: 437-443. (Pubitemid 40488372)